Genentech's Columvi drug shows positive overall survival results in Phase III STARGLO study for relapsed/refractory diffuse large B-cell lymphoma.

Genentech's Columvi drug meets primary endpoint of overall survival in Phase III STARGLO study for relapsed or refractory diffuse large B-cell lymphoma, according to Genentech, a member of the Roche Group. The Phase III trial's results show positive results, demonstrating the potential of Columvi as a treatment option for patients with this type of lymphoma.

April 15, 2024
4 Articles

Further Reading